Trident Lifeline

Trident Lifeline Current Assets

Delisted·Sep 16, 2026

The Current Assets of Trident Lifeline (543616.BO) as of Oct 30, 2026 is 903.71 M INR. In the previous year, Current Assets was 519.75 M INR — a change of 73.88% (higher).

Current Assets

903.71 MINR

YoY

73.88%

Last updated:

Current Assets of Trident Lifeline is 2025 903.71 M INR. Current Assets of Trident Lifeline was 2024 519.75 M INR. It decreases by 73.88% higher compared to the previous year.

The Trident Lifeline Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2020
28.28 M INR
Jan 1, 2021
77.41 M INR
Jan 1, 2022
106.46 M INR
Jan 1, 2023
485.47 M INR
Jan 1, 2024
519.75 M INR
Jan 1, 2025
903.71 M INR
The Trident Lifeline Current Assets history
YEARCurrent AssetsYoY
903.71 MINR+73.88%
519.75 MINR+7.06%
485.47 MINR+356.00%
106.46 MINR+37.52%
77.41 MINR+173.71%
28.28 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trident Lifeline Stock analysis

What does Trident Lifeline do? Trident Lifeline Ltd. generates revenue through the manufacturing and marketing of pharmaceutical products across seven geographical segments including India, Ghana, Kenya, Nigeria, Cameroon, Venezuela, and Rest of World. The company produces a diverse range of pharmaceutical formulations such as capsules, tablets, liquid ointments, gels, mouthwashes, and toothpaste under contract manufacturing on loan license. Its product portfolio features drugs like Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozoal, Anti Histamine, Anti-Hypertensive, Anti Lipidemic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical, and Non-Steroidal Anti-Inflammatory Drug (NSAIDS). The primary buyers are healthcare providers and consumers in the pharmaceutical market, with a focus on both domestic and international markets. The company's revenue streams are derived from the sale of its extensive product range, which includes both prescription and over-the-counter medications. By operating through multiple geographical segments, Trident Lifeline Ltd. caters to a broad customer base across different regions, ensuring consistent demand for its pharmaceutical formulations. The contract manufacturing model under loan license allows the company to leverage partnerships without significant capital investment, optimizing production costs and scalability. Trident Lifeline Ltd. targets healthcare providers and consumers seeking affordable pharmaceutical solutions, particularly in emerging markets. Its product offerings address a wide spectrum of health needs, from common ailments like diarrhea and fungal infections to chronic conditions such as diabetes and hypertension. This strategic focus on diverse drug categories ensures steady demand across its operational segments, supporting sustainable revenue growth. Trident Lifeline is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trident Lifeline stock

Current Assets of Trident Lifeline is 903.71 M INR in 2025.

Current Assets of Trident Lifeline changed from 519.75 M INR to 903.71 M INR, representing a 73.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Trident Lifeline since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Trident Lifeline historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trident Lifeline

All Key Metrics — Trident Lifeline